演題詳細

ポスター / Poster

ポスター 10 (Poster 10) :CML:臨床 2

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
増子 正義 (Masayoshi Masuko):1
1:新潟大学医歯学総合病院 高密度無菌治療部
 
前へ戻る

Successful treatment with nilotinib for secondary CML following TS-1 therapy for gastric cancer

演題番号 : PS-1-71

宮原 裕子 (Yasuko Miyahara):1、堀澤 欣史 (Yoshihito Horisawa):1、五島 悠太 (Yuta Goto):1、松井 道志 (Masashi Matsui):1、伊藤 満 (Mitsuru Itoh):1、山本 栄司 (Eiji Yamamoto):2

1:Dept.Hematology, Kyoto City Hospital, Kyoto, Japan、2:Depat. Surgery, Kyoto City Hospital, Kyoto, Japan

 

[Introduction] Therapy related leukemia, for example, acute myeloid leukemia and myelodysplastic syndrome, has been characterized, but secondary chronic myeloid leukemia is rare. On the other hand, adjuvant chemotherapy by S-1 for gastric cancer following gastrectomy is considered as standard treatment in Japan, but hematological adverse events were rare.[Case] A 74-year-old man received total gastrectomy for gastric cancer in May 2008 and was subsequently treated with oral anti metabolite TS-1 for 12 months. After three years disease free interval for gastric cancer, he was pointed out the enlargement of superior paratracheal lymph node on follow up CT examination, so he received TS-1 therapy again in September 2011. Leukocytosis was found in May 2012. Bone marrow aspiration showed myeloid hyperplasia without an increase of myeloblasts. Cytogenetic study revealed Ph-chromosome and diagnosis of chronic myeloid leukemia in chronic phase was made. He received administration of nilotinib resulted in complete hematological response after one month. Moreover, complete cytogenetic response was achieved three month after the beginning of nilotinib. [Conclusion] We report a rare case of secondary chronic myeloid leukemia following chemotherapy with TS-1 for gastric cancer. The present case is the first report of the treatment effect by nilotinib for secondary chronic myeloid leukemia.

前へ戻る